{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:56:50Z","timestamp":1790614610279,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015758","name":"Novo Nordisk Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015758","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s12325-022-02385-x","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T06:03:58Z","timestamp":1671602638000},"page":"920-933","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Once-Weekly Semaglutide Use in Type\u00a02 Diabetes: Real-World Data from the SURE Netherlands Observational Study"],"prefix":"10.1007","volume":"40","author":[{"given":"Bruce H. R.","family":"Wolffenbuttel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel P.","family":"Brugts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei-Mircea","family":"Catarig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aloysius G.","family":"Lieverse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap","family":"van Soest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,21]]},"reference":[{"key":"2385_CR1","unstructured":"Rijksinstituut voor Volksgezondheid en Milieu. Diabetes Mellitus, 2018. https:\/\/www.volksgezondheidenzorg.info\/onderwerp\/diabetes-mellitus. Accessed Apr 2022."},{"key":"2385_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-000705","volume":"7","author":"B Hunt","year":"2019","unstructured":"Hunt B, Malkin SJP, Moes RGJ, et al. Once-weekly semaglutide for patients with type\u00a02 diabetes: a cost-effectiveness analysis in the Netherlands. BMJ Open Diabetes Res Care. 2019;7: e000705. https:\/\/doi.org\/10.1136\/bmjdrc-2019-000705.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2385_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1471-2458-8-91","volume":"8","author":"A Moser","year":"2008","unstructured":"Moser A, van der Bruggen H, Widdershoven G, et al. Self-management of type\u00a02 diabetes mellitus: a qualitative investigation from the perspective of participants in a nurse-led, shared-care programme in the Netherlands. BMC Public Health. 2008;8:91.","journal-title":"BMC Public Health"},{"key":"2385_CR4","doi-asserted-by":"crossref","unstructured":"Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: Management of hyperglycemia in Type\u00a02 Diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43:487\u201393.","DOI":"10.2337\/dci19-0066"},{"key":"2385_CR5","unstructured":"Nederlands Huisartsen Genootschap (NHG). NHG-werkgroep Diabetes mellitus type 2. NHG-Standaard Diabetes mellitus type 2, www.nhg.org. 2018. https:\/\/richtlijnen.nhg.org\/standaarden\/diabetes-mellitus-type-2. Accessed June 2022."},{"key":"2385_CR6","unstructured":"Nederlandse Internisten Vereniging. Diabetes mellitus type\u00a02 in the second line. https:\/\/richtlijnendatabase.nl\/richtlijn\/diabetes_mellitus_type_2_in_de_tweede_lijn\/startpagina_bij_dm2_in_de_tweede_lijn.html. Accessed June 2022."},{"key":"2385_CR7","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","volume":"58","author":"J Lau","year":"2015","unstructured":"Lau J, Bloch P, Schaffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58:7370\u201380.","journal-title":"J Med Chem"},{"key":"2385_CR8","unstructured":"European Medicines Agency. Ozempic 0.5 mg solution for injection in pre-filled pen. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ozempic-epar-product-information_en.pdf. Accessed June 2022."},{"key":"2385_CR9","unstructured":"Food and Drug Administration. Ozempic 0.5 mg\/1.0 mg injection prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209637s003lbl.pdf. Accessed June 2022."},{"key":"2385_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","volume":"5","author":"C Sorli","year":"2017","unstructured":"Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type\u00a02 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5:251\u201360.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2385_CR11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","volume":"5","author":"B Ahr\u00e9n","year":"2017","unstructured":"Ahr\u00e9n B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type\u00a02 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5:341\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2385_CR12","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2337\/dc17-0417","volume":"41","author":"AJ Ahmann","year":"2018","unstructured":"Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type\u00a02 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41:258\u201366.","journal-title":"Diabetes Care"},{"key":"2385_CR13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"VR Aroda","year":"2017","unstructured":"Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-I patients with type\u00a02 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5:355\u201366.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2385_CR14","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1210\/jc.2018-00070","volume":"103","author":"HW Rodbard","year":"2018","unstructured":"Rodbard HW, Lingvay I, Reed J, et al. Semaglutide added to basal insulin in type\u00a02 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. 2018;103:2291\u2013301.","journal-title":"J Clin Endocrinol Metab"},{"key":"2385_CR15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","volume":"6","author":"RE Pratley","year":"2018","unstructured":"Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type\u00a02 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6:275\u201386.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2385_CR16","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","volume":"7","author":"I Lingvay","year":"2019","unstructured":"Lingvay I, Catarig AM, Frias JP, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type\u00a02 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7:834\u201344.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2385_CR17","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","volume":"7","author":"B Zinman","year":"2019","unstructured":"Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type\u00a02 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7:356\u201367.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2385_CR18","doi-asserted-by":"crossref","unstructured":"Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1\u20133 oral antidiabetic drugs in subjects with type\u00a02 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46:100\u20139.","DOI":"10.1016\/j.diabet.2019.101117"},{"key":"2385_CR19","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","volume":"35","author":"L Blonde","year":"2018","unstructured":"Blonde L, Khunti K, Harris SB, et al. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35:1763\u201374.","journal-title":"Adv Ther"},{"key":"2385_CR20","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1111\/dom.14468","volume":"23","author":"JF Yale","year":"2021","unstructured":"Yale JF, Catarig AM, Grau K, et al. Use of once-weekly semaglutide in patients with type\u00a02 diabetes in routine clinical practice: results from the SURE Canada multicentre, prospective, observational study. Diabetes Obes Metab. 2021;23:2269\u201378.","journal-title":"Diabetes Obes Metab"},{"key":"2385_CR21","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.pcd.2021.06.008","volume":"15","author":"NR Ekberg","year":"2021","unstructured":"Ekberg NR, Bodholdt U, Catarig AM, et al. Real-world use of once-weekly semaglutide in patients with type\u00a02 diabetes: results from the SURE Denmark\/Sweden multicentre, prospective, observational study. Prim Care Diabetes. 2021;15:871\u20138.","journal-title":"Prim Care Diabetes"},{"key":"2385_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108931","volume":"178","author":"G Rudofsky","year":"2021","unstructured":"Rudofsky G, Catarig AM, Favre L, et al. Real-world use of once-weekly semaglutide in patients with type\u00a02 diabetes: results from the SURE Switzerland multicentre, prospective, observational study. Diabetes Res Clin Pract. 2021;178:108931. https:\/\/doi.org\/10.1016\/j.diabres.2021.108931.","journal-title":"Diabetes Res Clin Pract"},{"key":"2385_CR23","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1007\/s13300-021-01141-8","volume":"12","author":"P Holmes","year":"2021","unstructured":"Holmes P, Bell HE, Bozkurt K, et al. Real-world use of once-weekly semaglutide in type\u00a02 diabetes: results from the SURE UK multicentre, prospective, observational study. Diabetes Ther. 2021;12:2891\u2013905.","journal-title":"Diabetes Ther"},{"key":"2385_CR24","doi-asserted-by":"crossref","unstructured":"World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 2013;310:2191\u20134.","DOI":"10.1001\/jama.2013.281053"},{"key":"2385_CR25","unstructured":"International Society for Pharmacoepedimiology. Guidelines for Good Pharmacoepidemiology Practices (GPP). Revision 2 2007. https:\/\/www.pharmacoepi.org\/resources\/policies\/guidelines-08027\/. Accessed June 2022."},{"key":"2385_CR26","doi-asserted-by":"crossref","unstructured":"Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473\u201383.","DOI":"10.1097\/00005650-199206000-00002"},{"key":"2385_CR27","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.1464-5491.1994.tb00316.x","volume":"11","author":"C Bradley","year":"1994","unstructured":"Bradley C, Gamsu DS. Guidelines for encouraging psychological well-being: report of a working group of the World Health Organization Regional Office for Europe and International Diabetes Federation European Region St Vincent Declaration Action Programme for Diabetes. Diabet Med. 1994;11:510\u20136.","journal-title":"Diabet Med"},{"key":"2385_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1477-7525-5-57","volume":"5","author":"C Bradley","year":"2007","unstructured":"Bradley C, Plowright R, Stewart J, et al. The Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) evaluated in insulin glargine trials shows greater responsiveness to improvements than the original DTSQ. Health Qual Life Outcomes. 2007;5:57.","journal-title":"Health Qual Life Outcomes"},{"key":"2385_CR29","doi-asserted-by":"crossref","unstructured":"Sorli C, Harashima S-I, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in subjects with type 2 diabetes (SUSTAIN 1). In: ENDO 2016\u201498th Annual Meeting of the Endocrine Society 2016;37:OR15\u20131.","DOI":"10.1016\/j.jcjd.2016.08.017"},{"key":"2385_CR30","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1111\/dom.14117","volume":"22","author":"RE Brown","year":"2020","unstructured":"Brown RE, Bech PG, Aronson R. Semaglutide once weekly in people with type\u00a02 diabetes: real-world analysis of the Canadian LMC diabetes registry (SPARE study). Diabetes Obes Metab. 2020;22:2013\u201320.","journal-title":"Diabetes Obes Metab"},{"key":"2385_CR31","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s13300-021-01015-z","volume":"12","author":"DM Williams","year":"2021","unstructured":"Williams DM, Ruslan AM, Khan R, et al. Real-world clinical experience of semaglutide in secondary care diabetes: a retrospective observational study. Diabetes Ther. 2021;12:801\u201311.","journal-title":"Diabetes Ther"},{"key":"2385_CR32","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.clinthera.2021.03.003","volume":"43","author":"J Visaria","year":"2021","unstructured":"Visaria J, Uzoigwe C, Swift C, et al. Real-world effectiveness of once-weekly semaglutide from a US commercially insured and medicare advantage population. Clin Ther. 2021;43:808\u201321.","journal-title":"Clin Ther"},{"key":"2385_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14655","volume":"38","author":"KB Hansen","year":"2021","unstructured":"Hansen KB, Svendstrup M, Lund A, et al. Once-weekly subcutaneous semaglutide treatment for persons with type\u00a02 diabetes: real-world data from a diabetes out-patient clinic. Diabet Med. 2021;38: e14655. https:\/\/doi.org\/10.1111\/dme.14655.","journal-title":"Diabet Med"},{"key":"2385_CR34","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1111\/dom.13816","volume":"21","author":"J Jendle","year":"2019","unstructured":"Jendle J, Birkenfeld AL, Polonsky WH, et al. Improved treatment satisfaction in patients with type\u00a02 diabetes treated with once-weekly semaglutide in the SUSTAIN trials. Diabetes Obes Metab. 2019;21:2315\u201326.","journal-title":"Diabetes Obes Metab"},{"key":"2385_CR35","unstructured":"Zorginstituut Nederland. GVS advice extension 2016. https:\/\/www.zorginstituutnederland.nl\/publicaties\/adviezen\/2016\/09\/22\/gvs-advies-uitbreiding-bijlage-2-voorwaarden-glp-1-agonisten-bij-diabetes-mellitus-type-2. Accessed June 2022."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02385-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02385-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02385-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T07:24:09Z","timestamp":1678087449000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02385-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,21]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["2385"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02385-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,21]]},"assertion":[{"value":"28 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}